CT-1812 is under clinical development by Cognition Therapeutics and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CT-1812’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CT-1812 (CT-018120, Elayta) is under development for the treatment of mild to moderate Alzheimer's disease, Parkinson’s disease, lewy body dementia and dry age related macular degeneration. It is administered orally in form of capsule. It is a small molecule which acts by targeting sigma-2/PGRMC1 and Abeta (Amyloid Beta Peptide) oligomers.
Cognition Therapeutics overview
Cognition Therapeutics (CogRx) is a drug discovery and development company. It discovers and develops small molecule therapeutics for Alzheimer’s disease and other neurocognitive disorders. The company uses its proprietary biology and chemistry platforms for the development of novel drug targets and disease-modifying therapies for the treatment of central nervous system disorders. It conducts clinical trials on its drug candidate CT1812 for the treatment of Alzheimer’s disease. The company uses screening strategies to identify small molecules capable of blocking the central toxicity of soluble oligomeric proteins. CogRx is headquartered in Purchase, New York, the US.
For a complete picture of CT-1812’s drug-specific PTSR and LoA scores, buy the report here.